Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

May 17, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Chloroquine, Hydroxychloroquine hurts COVID-19 patients with Cardiac Disease

COVID-19 Life Sciences Recruitment at ICMR-NIV With Rs. 54,000 pm Salary

Govt ICFRE Life Sciences Project Fellow Recruitment | Applications Invited

Chloroquine, Hydroxychloroquine hurts COVID-19 patients with Cardiac Disease
  • BiotechToday
  • World

Chloroquine, Hydroxychloroquine hurts COVID-19 patients with Cardiac Disease

bioxone November 7, 2020November 7, 2020

Devyani Goswami, Amity University Kolkata

 Right after in the early months of the pandemic the US government has asked for a huge supply of hydroxychloroquine from the Indian government as the primary drug to be used in the treatment of SARS-CoV-19. Though after a few months both hydroxychloroquine and chloroquine were considered to be an ineffective rather harmful drug for treating COVID-19 patients. 

For the past 70 years, hydroxychloroquine and chloroquine have been used as the primary drug for treating non-resistant malaria, SLE, RA. France and China have conducted studies where it proved that Covid-19 patients treated with hydroxychloroquine and chloroquine had 100% improvement and were declared disease-free. But later studies from the US stated that both of these drugs have adverse effects on patients suffering from Cardiac disease, SLE, and RA. 

The study was conducted with all the published articles on cardiac disease, hydroxychloroquine, and chloroquine in the past 20 years (2000-2020). 702,274 reports were obtained from the FDA FAERS database and after a thorough analysis of these databases, the final report was created.

Patients with cardiac diseases have higher chances of facing adverse effects on treatment with hydroxychloroquine and chloroquine. Although the level of adversity for hydroxychloroquine is lower than chloroquine, it remains somewhere equal.  Age, sex, weight, disease stage, NSAID, Aspirin were also the major factors, chloroquine had co-administration on these factors. SLE patients have more risk than RA patients on the administration of these drugs. It was also observed that usage of Aspirin along with these drugs had positive effects but certain reports for negative effects were also observed.

Till the discovery of a perfect vaccination again SARS-CoV-19, treatment of the patients with a certain known drug is the ultimate step. But to be sure the effects of hydroxychloroquine and chloroquine should not be trusted blindly.

Also read: Gene therapy clinical trials for rare Angelman syndrome put on hold

REFERENCE: Cardiac adverse events associated with Chloroquine and Hydroxychloroquine exposer in 20 years of drug safety surveillance reports – Issac V. Cohen et al. https://www.nature.com/articles/s41598-020-76258-0

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged cardiac disease Chloroquine COVID-19 Hydroxychloroquine Malaria rheumatoid arthritis (RA) systemic lupus erythematosus (SLE)

One thought on “Chloroquine, Hydroxychloroquine hurts COVID-19 patients with Cardiac Disease”

  1. Pingback: India set to begin the COVID-19 vaccination soon - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

Govt ICFRE Life Sciences Project Fellow Recruitment | Applications Invited

bioxone November 7, 2020

-Shristi Sharma, Team bioXone ICFRE Life Sciences Project Fellow Recruitment – Applications Invited. ICFRE – Institute of Forest Biodiversity is hiring for msc jobs. MSc candidates are requested to attend the walk-in that has been scheduled for Junior Project Fellow positions at IFB as per the details given below:  Indian Council of Forestry Research and […]

Related Post

  • BiotechToday
  • World

The connection between Winter Snow Melting and Water Resources!!!

bioxone April 14, 2021April 14, 2021

Sampriti Roy, University of Calcutta Accelerated climate change due to global warming is a well-known reality today. While the concept of climate change is unknown to few, there remain many grey areas about the effects of this ongoing phenomenon. This calls for rigorous research and the same is currently being done all over the world […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Lateral flow device (LFD): A mass testing technique for COVID-19

bioxone June 6, 2021June 6, 2021

Ananya Dutta, Bose Institute Various national and international health organizations have emphasized the significance of testing each and every individual in a population and ensuing the contact tracing in order to arrest the outspread of the COVID-19 virus. The existing diagnostic approach is a two-step procedure involving a reverse transcriptase-polymerase chain reaction followed by real-time […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • India

MARK4- One of the key players behind the onset of AD

bioxone October 28, 2020October 28, 2020

Avipsha Datta, Department of Biophysics, University of Calcutta Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that impairs brain function and memory. Neurons degenerate, disrupting the neural networks and thereby destroys our memory and other important motor functions. AD is thought to be caused by the abnormal build-up of proteins aggregates in and around the […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy